Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-BCT-100 in Advanced HCC
NCT01092091Phase 2Completed
- Sponsor
- Bio-Cancer Treatment International Limited
- Start
- Mar 2010
- Primary completion
- Feb 2012
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arginase in hepatocellular carcinoma (HCC), sponsored by Bio-Cancer Treatment International Limited. Primary endpoint: Objective Tumor Response at 12 weeks. Started Mar 2010; status: completed.
02
Drugs
arginase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01092091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01092091.